Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Moved Down to “Sell” by Wall Street Zen

Wall Street Zen downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock opened at $12.50 on Friday. The stock has a 50 day moving average of $13.09 and a 200 day moving average of $13.27. Enanta Pharmaceuticals has a 12 month low of $10.20 and a 12 month high of $17.15. The firm has a market cap of $364 million, a PE ratio of -5.19 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The firm had revenue of $14.36 million during the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. As a group, equities research analysts forecast that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ENTA. Wellington Management Group LLP increased its position in shares of Enanta Pharmaceuticals by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company’s stock valued at $1,190,000 after purchasing an additional 6,673 shares during the last quarter. Bank of America Corp DE purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at $314,000. Jupiter Topco LLC purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at $53,252,000. ADAR1 Capital Management LLC bought a new stake in Enanta Pharmaceuticals in the second quarter worth $19,603,000. Finally, Legal & General Group Plc bought a new stake in Enanta Pharmaceuticals in the second quarter worth $41,000. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.